FTC BOMBSHELL: Clinics Face Massive FRAUD Probe

Federal Trade Commission website homepage screenshot.

After years of unchecked medical experimentation on children, the Federal Trade Commission has finally launched a sweeping investigation into alleged deception and fraud in the transgender industry, aiming right at the heart of so-called “gender-affirming care” for minors—a move that’s left the activist medical complex scrambling for cover, and parents across America demanding answers.

At a Glance

The FTC is investigating deceptive marketing and practices in gender-affirming care for minors, with potential for major regulatory crackdowns.
The Trump administration’s executive order ended federal support for these interventions, fueling state and federal probes.
DOJ, CMS, and the FBI have joined the investigation, targeting clinics, drug makers, and hospitals.
Detransitioners and parents are coming forward, alleging they were misled and harmed by the industry’s practices.

FTC Targets Deceptive Practices in Gender Medicine for Kids

The Federal Trade Commission, under new leadership and emboldened by a conservative mandate, is finally doing what common sense and basic decency have demanded for years: digging into the murky world of gender medicine for children. On July 9, 2025, the FTC hosted a public workshop—no, not a feel-good panel, but a full-on evidentiary hearing—on whether providers of so-called “gender-affirming care” have crossed the line into outright fraud. Claims about puberty blockers being “completely reversible,” cross-sex hormones as “life-saving,” and surgeries on minors as “medically necessary”—all are under the microscope. The agency is probing whether these interventions were marketed using deceptive tactics, whether risks were downplayed, and if minors and their families were ever given the truth, the whole truth, and nothing but the truth.

This is not just about misleading advertisements. The FTC wields the power to punish companies and providers that make false or unsupported health claims, and it’s looking at clinics, drug manufacturers, and even advocacy organizations that have been pushing “gender transitions” for children. The workshop drew testimony from parents, detransitioners who say they were butchered in the name of “affirmation,” and whistleblowers from inside the medical establishment who allege a pattern of systematic deception. If the facts are as damning as they appear, lawsuits and penalties could be just the beginning.

Federal and State Agencies Join Forces

The Trump administration’s executive order earlier this year slammed the brakes on federal support for gender interventions on minors, calling them “radical and false.” State attorneys general, led by figures like Pam Bondi, didn’t waste a second—immediately launching investigations into clinics and drug companies. The Department of Justice has issued nearly 20 subpoenas to clinics and pharmaceutical manufacturers, demanding internal documents on consent practices, marketing materials, and patient outcomes. The Centers for Medicare and Medicaid Services sent letters to hospitals in May, demanding proof that they actually obtained informed consent before performing irreversible procedures on children. Even the FBI is involved, collecting public tips about unethical providers. This is the kind of full-court press the American people have been demanding for years, not just platitudes about “inclusion.”

On the legal front, the Supreme Court recently upheld Tennessee’s ban on these interventions for minors. That’s a green light for states to take up the fight and protect their most vulnerable citizens, while federal agencies comb through the wreckage left by years of activist medicine run wild. And let’s be clear: the FTC has a long and proud tradition of cracking down on snake-oil salesmen and quacks—now, it’s finally turning that scrutiny on the gender industry.

Industry Under Fire, Families Demand Accountability

For years, anyone who dared question the dogma of “gender-affirming care” was shouted down as a bigot or a science denier. Now, with the credibility of the industry crumbling, parents and detransitioners are finally being heard. Testimonies at the FTC workshop included stories from young adults who say they were fast-tracked through dangerous treatments, only to regret it once the irreversible damage was done. Parents described being pressured, misled, and stonewalled by clinics more interested in ideology than informed consent. Dr. Miriam Grossman, representing the advocacy group Do No Harm, laid out decades of evidence suggesting fraud and deception were not the exception, but the rule.

The outcome of this investigation could redefine medical standards, force clinics to face lawsuits, and send a clear message: America’s children are not experimental subjects for activist agendas. The FTC’s next steps may include new regulations, enforcement actions, and penalties for violators. The healthcare industry is bracing for impact, while families, finally, see hope for accountability. Meanwhile, defenders of gender medicine continue to claim the high ground, insisting their methods are evidence-based—but the facts are now on trial, and the American public is watching.